Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
28.00
+1.15 (4.28%)
At close: Dec 10, 2025, 4:00 PM EST
28.11
+0.11 (0.39%)
After-hours: Dec 10, 2025, 7:56 PM EST
Agios Pharmaceuticals Revenue
Agios Pharmaceuticals had revenue of $12.88M in the quarter ending September 30, 2025, with 43.69% growth. This brings the company's revenue in the last twelve months to $44.79M, up 36.26% year-over-year. In the year 2024, Agios Pharmaceuticals had annual revenue of $36.50M with 36.07% growth.
Revenue (ttm)
$44.79M
Revenue Growth
+36.26%
P/S Ratio
36.04
Revenue / Employee
$91,785
Employees
488
Market Cap
1.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36.50M | 9.68M | 36.07% |
| Dec 31, 2023 | 26.82M | 12.58M | 88.36% |
| Dec 31, 2022 | 14.24M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 94.39M | 51.38M | 119.45% |
| Dec 31, 2017 | 43.01M | -26.88M | -38.46% |
| Dec 31, 2016 | 69.89M | 10.77M | 18.22% |
| Dec 31, 2015 | 59.12M | -6.24M | -9.55% |
| Dec 31, 2014 | 65.36M | 39.81M | 155.82% |
| Dec 31, 2013 | 25.55M | 442.00K | 1.76% |
| Dec 31, 2012 | 25.11M | 3.27M | 14.97% |
| Dec 31, 2011 | 21.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
AGIO News
- 2 days ago - Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia - GlobeNewsWire
- 21 days ago - Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript - Seeking Alpha
- 21 days ago - Why Shares in Agios Pharmaceuticals Got Crushed Today - The Motley Fool
- 21 days ago - Why Is Agios Pharmaceuticals Stock Sinking Today? - Benzinga
- 21 days ago - Agios Pharma reports mixed results in late-stage study for sickle cell disease drug - Reuters
- 21 days ago - Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease - GlobeNewsWire
- 5 weeks ago - Q3 2025 Highlights - Agios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones - Seeking Alpha
- 5 weeks ago - Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition - GlobeNewsWire